CD8 Depleted, Non-Engrafting, HLA Mismatched Unrelated Donor Lymphocyte Infusion in Patients With MDA and Secondary AML

  • End date
    Dec 1, 2024
  • participants needed
  • sponsor
    H. Lee Moffitt Cancer Center and Research Institute
Updated on 18 October 2022
myeloid leukemia
acute leukemia
ejection fraction
secondary acute myeloid leukemia
acute promyelocytic leukemia


The purpose of the study is to determine the safety of an investigational treatment for myelodysplastic syndrome (MDS) after the first therapy (such as azacitidine or decitabine) stops working or after progression of MDS to acute myeloid leukemia (AML). Funding source - FDA OOPD.


The purpose of the study is to determine the safety of an investigational treatment for myelodysplastic syndrome (MDS) after the first therapy (such as azacitidine or decitabine) stops working or after progression of MDS to acute myeloid leukemia (AML).

Patients with advanced MDS are treated with hypomethylating agents (HMAs) such as azacitidine or decitabine. These medications can be effective for a few months to a few years, but usually lose effect eventually. This study is attempting to design a therapy called "non-engrafting, CD8 depleted donor lymphocyte infusion" or "NE-DLI" as a treatment for these diseases.

Condition Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia
Treatment Standard of care chemotherapy, CD8 Depleted, Non-engrafting,HLA mismatched unrelated donor lymphocytes
Clinical Study IdentifierNCT04620681
SponsorH. Lee Moffitt Cancer Center and Research Institute
Last Modified on18 October 2022


Yes No Not Sure

Inclusion Criteria

Myelodysplastic Syndrome (MDS) having failed hypomethylating agent (HMA)
therapy cohort
Age 18-79 years, inclusive
Pathologically confirmed MDS or myelodysplastic/myeloproliferative overlap (MDS/MPN)
IPSS-R score intermediate, high or very high
Must have failed therapy with an HMA (defined as lack of response by International Working Group criteria (1) or intolerance of the drug)
Secondary Acute Myeloid Leukemia (sAML)
Pathologically confirmed AML according to World Health Organization (WHO) criteria
Evidence of an antecedent hematologic disorder (AHD) prior to acute leukemia including a known prior diagnosis of MDS, MPN or MDS/MPN or data suggestive of an AHD such as cytopenias, fibrosis, macrocytic anemia, cellular or dysplasia at or prior to the time of diagnosis. If available, MDS-defining karyotypes (-7/del(7q), -5/del(5q), del(13q), del(11q), del(12p), t(12p), del(9q), idic(X)(q13), t(17p) (unbalanced translocations) or i(17q) (ie, loss of 17p), t(11;16)(q23;p13.3), t(3;21)(q26.2;q22.1), t(1;3)(p36.3;q21), t(2;11)(p21;q23), inv(3)(q21q26.2), t(6;9)(p23;q34)) or somatic mutations in multiple genes including p53, TET2, JAK2, CALR, MPL, ASXL1, RUNX1, SRSF2, SF3B1, U2AF1, ZRSR2, ASXL1, EZH2, BCOR, or STAG2 would also confirm eligibility
Age 60-79 years, inclusive
May be previously untreated
For both cohorts
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
Deemed eligible to receive cytotoxic chemotherapy
Creatinine clearance (CrCl)>50ml/min
Total bilirubin <2 mg/dL (except for patients with Gilbert's disease), AST and ALT < 3x ULN
Left Ventricular Ejection Fraction ≥ 50%
Willing and able to participate in study assessments

Exclusion Criteria

Patients who have had systemic chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier. Hydroxyurea during this period may be given as a bridging therapy to maintain disease stability while awaiting treatment. Intrathecal chemotherapy within this time frame is permitted. Intrathecal chemotherapy may be continued during protocol therapy in order to consolidate or maintain a central nervous system (CNS) remission, but not to treat active CNS disease
Acute promyelocytic leukemia, or the presence of t(15;17)
Patients receiving any other investigational agents
Uncontrolled concurrent illness including, but not limited to, ongoing and uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
Pregnant women are excluded from this study because there is an unknown but potential risk for adverse events in the fetus. Breastfeeding should be discontinued if the mother is treated. These potential risks may also apply to other agents used in this study
Patients who have any debilitating medical or psychiatric illness that would preclude their giving informed consent or their receiving optimal treatment and follow-up
Patients with a poor functional status of ECOG 3-4, or otherwise deemed unfit to tolerate induction chemotherapy
Patients with blastic transformation of chronic myelogenous leukemia are ineligible
Exposure to a humanized mouse chimeric antibody, as this could sensitize patients to components of the CD8 depletion column that may be present in small amounts in the cell product
Prior allogenic hematopoietic cell transplant
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note